MaxCyte, Inc. (NASDAQ:MXCT) Stake Raised by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC grew its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 66.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,230,182 shares of the company's stock after purchasing an additional 890,353 shares during the period. Chevy Chase Trust Holdings LLC owned approximately 2.10% of MaxCyte worth $6,088,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rhumbline Advisers grew its holdings in MaxCyte by 1.6% during the 4th quarter. Rhumbline Advisers now owns 153,655 shares of the company's stock valued at $639,000 after buying an additional 2,402 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of MaxCyte by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,929 shares of the company's stock worth $249,000 after buying an additional 2,584 shares during the period. Invesco Ltd. raised its position in shares of MaxCyte by 8.5% in the 4th quarter. Invesco Ltd. now owns 49,096 shares of the company's stock worth $204,000 after buying an additional 3,848 shares during the period. Tower Research Capital LLC TRC raised its position in shares of MaxCyte by 123.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company's stock worth $31,000 after buying an additional 4,173 shares during the period. Finally, Valmark Advisers Inc. raised its position in shares of MaxCyte by 6.5% in the 1st quarter. Valmark Advisers Inc. now owns 123,203 shares of the company's stock worth $336,000 after buying an additional 7,549 shares during the period. Institutional investors and hedge funds own 68.81% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on MXCT. Stifel Nicolaus cut their price objective on MaxCyte from $11.00 to $9.00 and set a "buy" rating on the stock in a research report on Wednesday, March 12th. Wall Street Zen raised MaxCyte from a "sell" rating to a "hold" rating in a research report on Sunday, June 8th. Finally, BTIG Research set a $6.00 price objective on MaxCyte and gave the company a "buy" rating in a research report on Wednesday, March 12th.

MaxCyte Stock Down 4.3%

Shares of MaxCyte stock traded down $0.10 during trading hours on Friday, hitting $2.20. 1,145,939 shares of the company's stock traded hands, compared to its average volume of 626,688. The stock has a 50 day simple moving average of $2.39 and a 200-day simple moving average of $3.30. The company has a market cap of $234.12 million, a PE ratio of -5.50 and a beta of 1.27. MaxCyte, Inc. has a twelve month low of $2.00 and a twelve month high of $5.20.

MaxCyte (NASDAQ:MXCT - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The company had revenue of $10.39 million during the quarter, compared to the consensus estimate of $9.05 million. MaxCyte had a negative return on equity of 19.90% and a negative net margin of 110.92%. As a group, equities research analysts predict that MaxCyte, Inc. will post -0.42 EPS for the current year.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.